98%
921
2 minutes
20
Objective: To investigate the value of fibro-bronchoscopic cryosurgery combined with medication in the treatment of tracheobronchial tuberculosis (TBTB).
Methods: This study was designed as a prospective, randomized clinical trial. 96 patients with newly diagnosed TBTB were collected and divided into the study group (n = 48) and the control group (n = 48). Specifically, conventional anti-tuberculosis therapy was given to the control group, with the study group undergoing fibro-bronchoscopic cryosurgery combined with topical administration. Afterward, the post-treatment response rate and adverse reaction indicators were collected for comparison.
Results: After treatment for 6 months, the study group was superior to the control group in terms of clinical efficacy (P = 0.013), negative conversion rate of acid-fast bacilli (P = 0.014), and lesion recovery (P = 0.003); after treatment for 6 months, the study and control groups exhibited no significant differences in the response rate of inflammatory infiltration (P = 1.000) and granulation proliferation (P = 0.061). Additionally, the study group showed a higher response rate of ulcer necrosis (P = 0.041) and cicatricial stenosis (P = 0.029) than the control group, with no significant differences observed in the incidence of adverse reactions between the 2 groups (P = 0.584). Moreover, the clinical efficacy in the study group was higher than that in the control group after treatment for 12 months (P < 0.001).
Conclusion: The application of fibro-bronchoscopic cryosurgery combined with topical administration on the basis of conventional anti-TB treatment can improve the clinical efficacy of TBTB patients and shorten the duration of treatment without increasing the incidence of adverse reactions.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12023616 | PMC |
http://dx.doi.org/10.1186/s12893-025-02812-0 | DOI Listing |
J Neurol Neurosurg Psychiatry
July 2025
The Alfred, Melbourne, Victoria, Australia.
Background: Corticosteroid treatment of multiple sclerosis (MS) relapses is assumed to improve the speed of relapse recovery, without modifying long-term disability risk. We aimed to re-evaluate this assumption in a large cohort of individuals with MS.
Methods: Individuals with clinically definite MS and ≥3 Expanded Disability Status Scale (EDSS) measurements over ≥12 months were identified within the international neuroimmunology registry MSBase.
BMJ Open
July 2025
Data Science Department, SESAN, Paris, France.
Purpose: The SEV-IDF programme aims to track infants born before 33 weeks of gestation, with very low birth weight (VLBW), neonatal encephalopathy or severe birth anomalies and perinatal disease. It employs an open, prospective, multicentric, population-based cohort approach. This report aims to describe the methodology employed to establish and manage the programme, details regarding follow-up procedures, baseline characteristics of the included infants, and highlights new research opportunities emerging from the "" (SEV-IDF) programme.
View Article and Find Full Text PDFAllergy
August 2025
Allergy Unit, Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
Background: There are conflicting data on a potential association between atopic dermatitis (AD) and cardiovascular diseases (CVD). The aim of this study was to further explore this connection and whether there are biomarkers indicating the risk for CVD in AD patients.
Methods: We included 677 AD patients and 79 nonatopic controls from an observational multicenter case-control study (ProRaD: Prospective longitudinal study investigating the remission phase in patients with atopic dermatitis and other allergy-associated diseases).
Sci Rep
January 2025
Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Theodor-Stern-Kai 7, 60596, Frankfurt am Main, Germany.
Community-acquired pneumonia (CAP) has a significant impact on public health, especially in light of the recent SARS-CoV-2 pandemic. To enhance disease characterization and improve understanding of the underlying mechanisms, a comprehensive analysis of the plasma lipidome, metabolome and proteome was conducted in patients with viral and bacterial CAP infections, including those induced by SARS-CoV-2. Lipidomic, metabolomic and proteomic profiling were conducted on plasma samples of 69 patients suffering either from viral or bacterial CAP.
View Article and Find Full Text PDFBMJ Open
October 2024
Consellería de Sanidade e o Servizo Galego de Saúde, Santiago de Compostela, Spain.
Introduction: Linezolid is a broadly used antibiotic to treat complicated infections caused by gram-positive bacteria. Therapeutic drug monitoring of linezolid concentrations is recommended to maximise its efficacy and safety, mainly haematological toxicity. Different pharmacokinetic/pharmacodynamic targets have been proposed to improve linezolid exposure: the ratio of the area under the concentration-time curve during a 24-hour period to minimum inhibitory concentration (MIC) between 80 and 120; percentage of time that the drug concentration remains above the MIC during a dosing interval greater than 85% and the trough concentration between 2 and 7 mg/L.
View Article and Find Full Text PDF